Clinical Trial Update: Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase II trial evaluating weekly paclitaxel (BMS-181339) in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED